Vaccines against Lyme disease: What happened and what lessons can we learn?

@article{Poland2011VaccinesAL,
  title={Vaccines against Lyme disease: What happened and what lessons can we learn?},
  author={Gregory A. Poland},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2011},
  volume={52 Suppl 3},
  pages={
          s253-8
        }
}
  • G. Poland
  • Published 1 February 2011
  • Biology
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
This article reviews events that led to the withdrawal of the only vaccine to prevent Lyme disease licensed in the United States. The primary issues that led to the vaccine's withdrawal appear to be a combination of vaccine safety concerns, sparked by a molecular mimicry hypothesis that suggested that the vaccine antigen, outer surface protein A, serves as an autoantigen and hence was arthritogenic; concerns raised by anti-vaccine groups regarding vaccine safety; vaccine cost; a difficult… 
View on PubMed
academic.oup.com
106 Citations
Highly Influential Citations
7
Background Citations
27
Methods Citations
1
Results Citations
1

Tables from this paper

106 Citations

Antigen Engineering Approaches for Lyme Disease Vaccines.
TLDR
Recent antigen engineering strategies that have paved the way for the development of next generation vaccines against Lyme disease, some of which have reached clinical testing are summarized.
Why is There Still no Human Vaccine Against Lyme Borreliosis?
TLDR
Recent data indicate that an effective vaccine may require a combination of several antigens or multiple epitopes based on vector-borne proteins and several outer membrane proteins of Borrelia.
Inner Workings: Lyme disease vaccines face familiar challenges, both societal and scientific
  • Leah Shaffer
  • Medicine
    Proceedings of the National Academy of Sciences
  • 2019
TLDR
The pressure is on to make the “perfect vaccine” against Lyme disease based on a vaccine for dogs that was released in 2016, says immunologist Richard Marconi, one of the researchers working on the dog vaccine–inspired approach.
A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development
TLDR
The current study further validates that the monovalent and multivalent LB vaccines result in mild local side effects and self-limiting systemic adverse effects, with the multivalent vaccine slightly more tolerable than themonovalent one.
Vaccines for tick-borne diseases and cost-effectiveness of vaccination: a public health challenge to reduce the diseases’ burden
TLDR
Cost-effectiveness of vaccination is a helpful tool in the decision making process to include novel vaccines in the national vaccination program or to extend current programs, and its role is only increasing.
The clinician's guide to the anti-vaccinationists' galaxy.
Vaccines for Lyme Borreliosis: Facts and Challenges
TLDR
This review aims to uncover and delineate various strategies and diverse technological approaches related to vaccine production, and characterize already tested vaccines, possibilities for their future development, and reasons for their failure.
Accepted Manuscript Review the Clinician's Guide to the Anti-vaccinationists' Galaxy the Clinician's Guide to the Anti-vaccinationists' Galaxy Department of Medicine
In this paper we briefly review three common immunological misconceptions that feature prominently among anti-vaccinationists, and in turn, fuel patient and parental concerns, questions, and fears…
Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics
TLDR
There is a need for continuous effort in research from all perspectives on LB, especially regarding prevention with novel vaccines, their development, clinical efficacy and cost–effectiveness, to further develop (cost-) effective strategies for prevention and control of the disease.
Recent Progress in Lyme Disease and Remaining Challenges
TLDR
Progress over the past 5 years in the understanding of Lyme and tick-borne diseases in the United States is summarized and remaining challenges are highlighted.
...
...

References

SHOWING 1-10 OF 24 REFERENCES
The prevention of Lyme disease with vaccine.
The Lyme vaccine: a cautionary tale
TLDR
In 1998, the FDA approved a new recombinant Lyme vaccine, LYMErix™, which reduced new infections in vaccinated adults by nearly 80%.
Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  • S. M. Hewitt
  • Medicine
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports
  • 1999
This report provides recommendations for use of a newly developed recombinant outer-surface protein A (rOspA) Lyme disease vaccine (LYMErix, SmithKline Beecham Pharmaceuticals) for persons aged 15-70…
Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
TLDR
Three injections of vaccine prevented most definite cases of Lyme disease or asymptomatic B. burgdorferi infection in 10,936 subjects in areas of the United States in which Lyme disease is endemic.
Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant
TLDR
Three injections of vaccine prevented most definite cases of Lyme disease or asymptomatic B. burgdorferi infection in 10,936 subjects in areas of the United States in which Lyme disease is endemic.
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.
TLDR
OspA vaccine was safe and effective in the prevention of Lyme disease and there was no significant increase in the frequency of arthritis or neurologic events in vaccine recipients.
Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults.
Arthritis following recombinant outer surface protein A vaccination for Lyme disease.
TLDR
The potential arthritogenic effect of OspA suggested by in vitro and animal studies finds a clinical correlate in these 4 cases of males who developed arthritis following recombinant OSPA vaccination.
Adverse event reports following vaccination for Lyme disease: December 1998-July 2000.
Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis.
TLDR
Molecular mimicry between a dominant T cell epitope of OspA and hLFA-1 may be an important factor in the persistence of joint inflammation in genetically susceptible patients with treatment-resistant Lyme arthritis.
...
...